ALFACELL CORP
NT 10-K, 1999-10-28
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MERRILL LYNCH USA GOVERNMENT RESERVES, NSAR-B, 1999-10-28
Next: CALVERT VARIABLE SERIES INC, 497, 1999-10-28




                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25

                                                         SEC File No.: 000-11088

                           NOTIFICATION OF LATE FILING

                    /X/Form 10-K / / Form 11-K / / Form 20-F
                           / /Form 10-Q / /Form N-SAR

                         For Period Ended: July 31, 1999

    Nothing in this form shall be construed to imply that the Commission has
                   verified any information contained herein.

- --------------------------------------------------------------------------------


     If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:

N/A
- --------------------------------------------------------------------------------


                                     PART I
                             REGISTRANT INFORMATION

ALFACELL CORPORATION
- --------------------------------------------------------------------------------
Full Name of Registrant


N/A
- --------------------------------------------------------------------------------
Former Name if Applicable


225 Belleville Avenue
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)


Bloomfield, New Jersey 07003
- --------------------------------------------------------------------------------
City, State and Zip Code





                                        1

<PAGE>



                                     PART II
                            RULES 12b-25 (b) AND (c)

     If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the
following should be completed. (Check box if appropriate)

/X/       (a)  The reasons described in reasonable detail in Part III of this
               form could not be eliminated without unreasonable effort or
               expense;

/X/       (b)  The subject annual report, semi-annual report/portion thereof,
               will be filed on or before the fifteenth calendar day following
               the prescribed due date; or the subject quarterly report/portion
               thereof will be filed on or before the fifth calendar day
               following the prescribed due date; and

          (c)  The accountant's statement or other exhibit required by Rule
               12b-25 (c) has been attached if applicable.

                                    PART III
                                    NARRATIVE

     State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F,
10-Q, N-SAR, or the transition report or portion thereof, could not be filed
within the prescribed time period.

     The Company's Chief Financial Officer, Gail E. Fraser, resigned effective
as of June 23, 1999. As a result, such officer's responsibilities have been
reassigned to others at the Company. This transition has caused a delay in
completing the Form 10-K. The Registrant does not have sufficient time to meet
filing requirements for Form 10-K.

                                     PART IV
                                OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this
     notification.


       Kuslima Shogen                (973)                   748-8082
- --------------------------------------------------------------------------------
         (Name)                     Area Code             (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter period that the
     registrant was required to file such report(s) been filed? If answer is no,
     identify report(s).

                                                                  /X/ Yes / / No

- --------------------------------------------------------------------------------


                                        2

<PAGE>





(3)  Is it anticipated that any significant change in results of operations from
     the corresponding period for the last fiscal year will be reflected by the
     earnings statements to be included in the subject report or portion
     thereof?

                                                                /  / Yes  /X/ No

     If so, attach an explanation of the anticipated change, both narratively
     and quantitatively, and, if appropriate, state the reasons why a reasonable
     estimate of the results cannot be made.

- --------------------------------------------------------------------------------


     ALFACELL CORPORATION, has caused this notification to be signed on its
behalf by the undersigned hereunto duly authorized.

Date: October 27, 1999

                                     By:   /s/ KUSLIMA SHOGEN
                                           ------------------------------
                                           Kuslima Shogen
                                           Chief Executive Officer






                                        3



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission